



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/052,926	01/16/2002	Jeffrey R. Sampson	2003309-0027 (Agilent 10	1042
7590 01/30/2007 AGILENT TECHNOLOGIES, INC. Legal Department, DL429 Intellectual Property Administration P.O. Box 7599 Loveland, CO 80537-0599			EXAMINER TUNG, JOYCE	
			ART UNIT 1637	PAPER NUMBER
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		01/30/2007	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/052,926	SAMPSON, JEFFREY R.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Joyce Tung	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 31 October 2006.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-35,67-101 and 144-149 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-35,67-101 and 144-149 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### DETAILED ACTION

The applicant's response filed 10/31/06 to the Office action has been entered. Claims 1-35, 67-101 and 144-149 are pending.

1. The rejection of claims 1-34, 67-100 and 144-147 under 35 U.S.C. 103(a) as being unpatentable over Baldarelli et al. (6,015,714, issued Jan. 18, 2000) in view of Sampson et al. (US 2004/0086880 A1, issued May 6, 2004) and the rejection of claims 35 and 101 under 35 U.S.C. 103(a) as being unpatentable over Baldarelli et al. (6,015,714, issued Jan. 18, 2000) in view of Sampson et al. (US 2004/0086880 A1, issued May 6, 2004) as applied to claims 1-34, 67-100 and 144-147 above, and further in view of Thorp et al. (5,871,918, issued Feb. 16, 1999) are withdrawn because of the argument.

### NEW GROUNDS OF REJECTIONS

#### *Claim Rejections - 35 USC § 103*

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. Claims 1-33, 67-76, 78-100 and 148-149 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baldarelli et al. (6,015,714, issued Jan. 18, 2000) in view of Brockhurst et al. (2003/0104376, issued Jun. 5, 2003).

Baldarelli et al. disclose a method for sequencing nucleic acid polymers. The description of the method of Baldarelli et al. is listed in claims 1-24 (See Abstract and column 23-24, claims 1-24). Modified bases are available including methylated bases (See column 8, lines 44-45). In

Art Unit: 1637

order to identify the monomers, conditions should be appropriate to avoid secondary structure in the polymer to be sequenced (See column 8, lines 53-54). Baldarelli et al. also disclose sequencing two different oligonucleotide homopolymers (See column 21, lines 55-67). The oligonucleotide homopolymers <sup>were</sup> ~~is~~ interpreted as the sequence with at least one repeat of a nucleotide sequence.

Baldarelli et al. do not disclose the nucleic acid molecule containing modified nucleotides that reduce secondary structure in the nucleic acid molecule, which are modified adenosine, modified thymine, modified guanosine and modified cytosine and the nucleic acid which is enzymatically produced by using a circular template.

Brockhurst et al. disclose a method of identifying or detecti<sup>ng</sup>~~on~~ a nucleic acid repeat region (See [0012]). A single stranded nucleic acid template is amplified with the repeat region (See [0012] and [0016]). The method used for amplification is rolling circle amplification ([0039]). Nucleotides used in either DNA or RNA include modified bases capable of base pairing with one of the conventional bases, adenine, cytosine, guanine, thymine and uracil. Such modified bases includes inosine (See [0051]).

One of ordinary skill in the art would have been motivated to apply the modified base in the method of Baldarelli et al. for sequencing a nucleic acid molecule as taught by Brockhurst et al. because by doing so the method of Brockhurst et al. is more efficient for analyzing nucleotide repeat regions (See pg. [0007]). The method of Brockhurst et al. also is practiced on single stranded template from a non-amplified nucleic acid molecule in which the template is subjected to PCR-rolling circle amplification (See pg. [0039]). It would have been prima facie obvious to

Art Unit: 1637

produce the nucleic acid with circular template and apply the modified base in the method of Baldarelli et al. for sequencing a nucleic acid molecule.

4. Claims 34, 77 and 144-147 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baldarelli et al. (6,015,714, issued Jan. 18, 2000) in view of Brockhurst et al. (2003/0104376, issued Jun. 5, 2003) as applied to claims 1-33, 67-76, 78-100 and 148-149 above, and further in view of Dellinger et al. (6,693,187, issued Feb. 17, 2004).

The teachings of Baldarelli et al. and Brockhurst et al. are set forth in section 3 above. None of the references above discloses the modified base as recited in claims 34, 77 and 144-147.

Dellinger et al disclose oligonucleotide synthesis with phosphinoamidite carboxylates and analogs thereof having reduced internucleotide charge (See column 1, lines 8-16). The nucleobase can be 2'-thiothymidine (See column 22, lines 44-67). The synthesized oligonucleotide is used in nucleic acid sequencing (See column 44, lines 15-29).

One of ordinary skill in the art would have been motivated to apply the synthesized oligonucleotide with the modified base as taught by Dellinger et al. in the method of Baldarelli et al. for sequencing a nucleic acid molecule because the synthesized oligonucleotide of Dellinger et al. has the feature of reducing internucleotide charge (See column 1, lines 8-16). It would have been prima facie obvious to apply the nucleic acid with the base modification, such as 2'-thiothymidine for sequencing a nucleic acid molecule.

5. Claims 35 and 101 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baldarelli et al. (6,015,714, issued Jan. 18, 2000) in view of Brockhurst et al. (2003/0104376,

Art Unit: 1637

issued Jun. 5, 2003) as applied to claims 1-33, 67-76, 78-100 and 148-149 above, and further in view of Thorp et al. (5,871,918, issued Feb. 16, 1999).

The references of Baldarelli et al. and Brockhurst et al. set forth in section 3 above do not disclose analyzing nucleic acid by electron tunneling.

Thorp et al. disclose a method of detecting a nucleic acid by using electron tunneling (See column 9, lines 30-55). The method may be used in a variety of applications, including DNA sequencing (See the Abstract).

One of ordinary skill in the art would have been motivated to modify the method of Baldarelli et al. by applying electron tunneling as taught by Thorp et al. since the electron tunneling is applied to DNA sequencing. It would have been prima facie obvious to apply the electron tunneling to the method of Baldarelli et al. to make the instant invention for sequencing DNA.


### Summary


6. No claims are allowed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (571) 272-0790. The examiner can normally be reached on Monday - Friday, 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Joyce Tung   
January 19, 2007

  
KENNETH R. HORLICK, PH.D  
PRIMARY EXAMINER

1/22/07